Phase 3 COPD Trial, Recruiting NCT06474039 Sponsor: Mahidol University Condition: COPD
Back to Copd

Phase 3 COPD Trial, Recruiting

NCT06474039
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific stage of COPD (called GOLD B), meaning they have had no more than one flare-up (worsening of symptoms) in the year before joining the study
  • People with this stage of COPD who have previously been treated with one or more types of inhaled airway-opening medications (known as long-acting bronchodilators), or short-acting bronchodilators
  • People who are able to read and agree to the study's participation documents

Who may not be able to join:

  • People who have or have had certain other lung conditions, such as tuberculosis (TB), lung cancer, damaged or scarred lung tissue, or bronchiectasis (a condition where the airways are widened and damaged), or who have other cancers or active heart disease
  • People who are currently taking long-term medications that suppress the immune system or long-term steroid tablets
  • People who are already being treated with a combination of three specific types of inhaled medications together (a combination of an inhaled steroid, and two types of bronchodilators)
  • People who are in the final stages of a terminal illness

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Kittipong Maneechotesuwan, MD,PhD, Siriraj Hospital

Phone: 0894996858

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Mahidol University
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
1 June 2026

Where this trial is recruiting

🇹🇭 Thailand

Primary endpoints

Changes in lung volume

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov